Therapeutic antibodies targeting the CTLA4/PD-1 pathways have revolutionized cancer immunotherapy by eliciting durable remission in patients with cancer. However, relapse following early response, attributable to primary and adaptive resistance, is frequently observed. Additional immunomodulatory pathways are being studied in patients with primary or acquired resistance to CTLA4 or PD-1 blockade. The DNAM1 axis is a potent coregulator of innate and adaptive immunity whose other components include the immunoglobulin receptors TIGIT, PVRIG, and CD96, and their nectin and nectin-like ligands. We review the basic biology and therapeutic relevance of this family, which has begun to show promise in cancer clinical trials. SIGNIFICANCE: Recent studies have outlined the immuno-oncologic ascendancy of coinhibitory receptors in the DNAM1 axis such as TIGIT and PVRIG and, to a lesser extent, CD96. Biological elucidation backed by ongoing clinical trials of single-agent therapy directed against TIGIT or PVRIG is beginning to provide the rationale for testing combination regimens of DNAM1 axis blockers in conjunction with anti-PD-1/PD-L1 agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/2159-8290.CD-20-1248 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation.
Exp Hematol
December 2024
Compugen, Ltd., Holon, Israel. Electronic address:
Therapeutic advances in treating patients with multiple myeloma (MM), including novel immunotherapies, have improved the disease control, but it remains incurable. Although traditional immune check point inhibitors have shown limited clinical benefit, targeting alternative immune-inhibitory pathways may offer a novel way to address relapsed disease. Blockade of the immune regulator TIGIT was shown to enhance antitumor immunity in preclinical MM models.
View Article and Find Full Text PDFThe Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.
Front Immunol
August 2024
The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
In recent years, immunotherapy has emerged as a crucial component of cancer treatment. However, its efficacy remains limited across various cancer types, highlighting unmet needs. Poliovirus receptor-related 2 (PVRL2) and Poliovirus receptor (PVR) are members of the Nectin and Nectin-like Molecules family, known for their role as cell-cell adhesion molecules.
View Article and Find Full Text PDFStructural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand Nectin-2.
Structure
July 2024
Beijing Life Science Academy, Beijing 102200, China; Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing 100080, China. Electronic address:
Nectin and nectin-like (Necl) co-receptor axis, comprised of receptors DNAM-1, TIGIT, CD96, PVRIG, and nectin/Necl ligands, is gaining prominence in immuno-oncology. Within this axis, the inhibitory receptor PVRIG recognizes Nectin-2 with high affinity, but the underlying molecular basis remains unknown. By determining the crystal structure of PVRIG in complex with Nectin-2, we identified a unique CC' loop in PVRIG, which complements the double-lock-and-key binding mode and contributes to its high affinity for Nectin-2.
View Article and Find Full Text PDFImmune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.
Haematologica
April 2024
Department of Hematology and Oncology, Dokkyo Medical University, Tochigi.
Acute myeloid leukemia (AML) is a hematologic malignancy that frequently relapses, even if remission can be achieved with intensive chemotherapy. One known relapse mechanism is the escape of leukemic cells from immune surveillance. Currently, there is no effective immunotherapy for AML because of the lack of specific antigens.
View Article and Find Full Text PDFDNAM-1 Immunoreceptor Protects Mice from Concanavalin A-Induced Acute Liver Injury by Reducing Neutrophil Infiltration.
J Immunol
September 2023
Department of Immunology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Article Synopsis
- DNAM-1 (CD226) is an activating receptor on T cells and NK cells that interacts with CD155 on various cell types, playing a key role in immune responses.
- In a study on acute liver injury induced by Concanavalin A (Con A), researchers found that DNAM-1-deficient (Cd226-/-) mice had more severe liver damage and higher levels of inflammatory markers IL-6 and TNF-α compared to normal mice.
- The study revealed that neutrophils contributed to the worsening of liver injury in DNAM-1-deficient mice, and that the DNAM-1-CD155 interaction helps regulate the production of the neutrophil attractant CXCL1 from liver cells
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!